• No results found

Development of an anitsense-mediated exon skipping therapy for Duchenne Muscular Dystrophy.

N/A
N/A
Protected

Academic year: 2021

Share "Development of an anitsense-mediated exon skipping therapy for Duchenne Muscular Dystrophy."

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Development of an anitsense-mediated exon skipping therapy for

Duchenne Muscular Dystrophy.

Aartsma-Rus, A.M.

Citation

Aartsma-Rus, A. M. (2005, February 10). Development of an anitsense-mediated exon

skipping therapy for Duchenne Muscular Dystrophy. Retrieved from

https://hdl.handle.net/1887/604

Version:

Corrected Publisher’s Version

License:

Licence agreement concerning inclusion of doctoral thesis in the

Institutional Repository of the University of Leiden

Downloaded from:

https://hdl.handle.net/1887/604

(2)

176

Curriculum Vitae

De auteur van dit proefschrift werd geboren op 12 september 19 7 7 te Leiden. In 19 9 5 behaalde zij haar VW O diploma aan de Gereformeerde S cholengemeenschap te Rotterdam, waarna ze begon met de studie Biomedische W etenschappen aan de U niversiteit Leiden. Tijdens deze studie liep zij stage bij de afdeling Maag-, Darm en Leverziekten van het Leids U niversitair Medisch Centrum, waar zij onder leiding van Dr. Corine Penning en Dr. A d Masclee onderzoek deed naar het effect van glucagon op het

eetgedrag. Vervolgens deed zij onder leiding van Ing. Els Jol, Dr. Bert 't Hart en Dr. Maarten van Tol onderzoek naar de humorale immuunrespons in een rhesus-apen model voor rhematoide arthritis bij het immunologisch laboratorium kindergeneeskunde van het Leids U niversitair Medisch Centrum en het Biomedical Primate Research Center te Rijswijk. Tijdens haar eindstage, die werd begeleid door Dr. Dorien Peters en Dr. Rachel Giles, zocht zij naar mutaties in Rubinstein-Tay bi patienten in het

Referenties

GERELATEERDE DOCUMENTEN

To develop the exon-skipping approach for larger groups of patients, AONs targeting additional exons of the gene would have to be developed, for example, AONs to skip exon 51,

As such, the applicability of skipping in- frame exons to bypass these mutations by single exon skip- ping is low (0.02 –0.8% of all patients [ 12]) making the clinical development

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded.

The studies described in this thesis have been performed at the Leiden University Medical Center, department of human genetics. This work was financially supported by the Dutch

Using this ‘B-peptide’ to deliver a PMO targeting exon 23 in mdx mice showed high levels of exon skipping and dystrophin protein, even in heart, in which skipping levels are

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded